<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101278119</journal-id>
<journal-id journal-id-type="pubmed-jr-id">34288</journal-id>
<journal-id journal-id-type="nlm-ta">Future Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Future Neurol</journal-id>
<journal-title-group>
<journal-title>Future neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1479-6708</issn>
<issn pub-type="epub">1748-6971</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32089651</article-id>
<article-id pub-id-type="pmc">7034938</article-id>
<article-id pub-id-type="doi">10.2217/fnl-2018-0040</article-id>
<article-id pub-id-type="manuscript">NIHMS1044634</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Fragile X- associated Neuropsychiatric Disorders: A Case Report</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Tan</surname>
<given-names>Maria Melinda</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dy</surname>
<given-names>Jeanne Barbara</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Salcedo-Arellano</surname>
<given-names>Maria Jimena</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tassone</surname>
<given-names>Flora</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Randi J</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis Health, Sacramento, CA, USA</aff>
<aff id="A2"><label>2</label>MedMom Institute for Human Development, Pasig City, Philippines</aff>
<aff id="A3"><label>3</label>Department of Psychology, University of the Philippines Diliman, Quezon City, Philippines</aff>
<aff id="A4"><label>4</label>Department of Pediatrics, The Medical City, Ortigas Avenue, Pasig City, Philippines</aff>
<aff id="A5"><label>5</label>Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, USA</aff>
<aff id="A6"><label>6</label>Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, Sacramento, California</aff>
<author-notes>
<fn fn-type="other" id="FN1">
<label>*</label>
<p id="P1">These authors contributed equally to this work.</p>
</fn>
<corresp id="CR1"><bold>Correspondence should be addressed to</bold>: Randi J Hagerman. MIND Institute UCDMC, 2825 50th Street, Sacramento, California, 95817; <email>rjhagerman@ucdavis.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P37"><bold>Conflicts of Interest</bold>: RH has received funding from Roche, Novartis, Neuren, Marinus, and Alcobra for carrying out treatment studies in patients with fragile X syndrome. She has also consulted with Fulcrum, Ovid and Zynerba regarding treatment studies in individuals with fragile X syndrome. The other authors declare no conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>5</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>5</month>
<year>2020</year>
</pub-date>
<volume>14</volume>
<issue>2</issue>
<elocation-id>10.2217/fnl-2018-0040</elocation-id>
<self-uri xlink:href="https://www.futuremedicine.com/doi/10.2217/fnl-2018-0040"></self-uri>
<abstract id="ABS1">
<p id="P2">Mutations in the Fragile X Mental Retardation 1 (<italic>FMR1</italic>) gene create a spectrum of developmental disorders in children in addition to neurodegenerative problems in older populations. Two types of mutations are recognized in the <italic>FMR1</italic> gene. The full mutation (&gt;200 CGG repeats) in the <italic>FMR1</italic> gene leads to Fragile X Syndrome which is the most common inherited cause of intellectual disability and autism, while the premutation (55 to 200 CGG repeats) identified among carriers leads to a range of problems linked to elevated levels of the <italic>FMR1</italic> mRNA leading to mRNA toxicity and occasionally mildly deficient FMRP levels. Two disorders among premutation carriers have been recognized namely: the Fragile X-associated Primary Ovarian Insufficiency (FXPOI) and Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). Recently, in order to recognize a group of associated disorders commonly found in premutation carriers and extensively reported in co-morbidities studies, a new distinctive name was proposed: Fragile X-associated Neuropsychiatric Disorders (FXAND). This paper will present a case report of a female premutation carrier who has encountered predominantly psychiatric problems, but also chronic pain and sleep disturbances consistent with FXAND.</p>
</abstract>
<kwd-group>
<kwd>
<italic>FMR1</italic>
</kwd>
<kwd>Fragile X-associated Neuropsychiatric Disorders</kwd>
<kwd>FXAND</kwd>
<kwd>premutation carrier</kwd>
<kwd>anxiety</kwd>
<kwd>depression</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>